New Pancreatic Cancer Research Reveals Therapy Targets

Key Points

• Researchers at Trinity College Dublin published a major review explaining why pancreatic cancer remains highly resistant to treatment.
• The study applies the updated “Hallmarks of Cancer” framework to pancreatic cancer in unprecedented detail.
• Scientists identified interconnected drivers, including genetic mutations, immune evasion, metabolic rewiring, tumour microenvironment changes, nerve interactions, and the microbiome.
• The review suggests combination-based therapies may offer stronger clinical potential than single-drug strategies.
• Experts also highlighted the importance of biomarker-led clinical trials and better laboratory models.

Pancreatic Cancer Research Reveals Why Treatment Resistance Persists

A new pancreatic cancer review from scientists at Trinity St James’s Cancer Institute explains why pancreatic cancer remains one of the deadliest cancers in oncology. Published in Cancer Letters, the study outlines how multiple biological systems interact to drive tumour progression and treatment resistance.

With only 13% of patients surviving beyond five years after diagnosis, this disease continues to face challenges related to late detection, aggressive tumour biology, and limited treatment options. Rather than focusing on a single pathway, researchers applied the updated “Hallmarks of Cancer” framework developed by Douglas Hanahan and Robert Weinberg to provide a broader systems-level understanding of the disease.

How the Tumour Microenvironment and Immune Evasion Drive Disease Progression

Researchers identified several interconnected mechanisms driving pancreatic cancer progression, including genetic mutations, tumour microenvironment changes, immune evasion, metabolic adaptation, tumour-nerve interactions, and microbiome activity. Lead author Laura Kane noted that cancer functions as a coordinated biological network rather than a single-pathway disease.

Key highlights from the review include:

• Single-agent therapies may provide limited long-term benefit in pancreatic cancer.
• Combination-based treatment strategies targeting multiple cancer hallmarks could improve therapeutic response.
• The findings may help guide biomarker-led clinical trials and future precision oncology approaches in gastrointestinal oncology.

Combination Therapies Could Shape the Future of Pancreatic Cancer Care

Senior author Stephen Maher noted that patient outcomes have improved only marginally despite decades of cancer research. The review provides a roadmap for developing next-generation therapies that better reflect the biological complexity of pancreatic tumours.

The authors also emphasize the need for biomarker-led clinical trials, improved preclinical laboratory models, and integrated therapeutic approaches capable of targeting several tumour-driving systems simultaneously.

Explore All Oncology CME Conferences and Online Courses 2026

For oncologists, oncology nurses, translational researchers, and multidisciplinary cancer care teams, the findings reinforce the importance of collaborative treatment strategies and precision oncology approaches in cancer management.

Source:

Trinity College Dublin